title: Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
authors.affiliation: aMedical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Rome bPharmacology Unit cMedical Oncology Unit dDepartment of Odontostomatology and Maxillofacial Surgery, Policlinico Le Scotte, University of Siena, Siena, Italy.
authors.forename: Edoardo
authors.initials: E
authors.lastname: Francini
authors.forename: Anna I
authors.initials: AI
authors.lastname: Fiaschi
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Bianco
authors.forename: Letizia
authors.initials: L
authors.lastname: Laera
authors.forename: Filippo
authors.initials: F
authors.lastname: Francini
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; C089740:abiraterone